Search details
1.
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
N Engl J Med
; 388(19): 1739-1754, 2023 May 11.
Article
in English
| MEDLINE | ID: mdl-37163621
2.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood
; 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38620072
3.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood
; 2024 Apr 15.
Article
in English
| MEDLINE | ID: mdl-38620092
4.
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLL.
Blood
; 141(12): 1425-1441, 2023 03 23.
Article
in English
| MEDLINE | ID: mdl-36179280
5.
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Blood
; 141(5): 519-528, 2023 02 02.
Article
in English
| MEDLINE | ID: mdl-36084320
6.
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mut.
Blood
; 142(11): 961-972, 2023 09 14.
Article
in English
| MEDLINE | ID: mdl-37363867
7.
Oncogenic role and target properties of the lysine-specific demethylase KDM1A in chronic lymphocytic leukemia.
Blood
; 142(1): 44-61, 2023 07 06.
Article
in English
| MEDLINE | ID: mdl-37023372
8.
High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations.
Blood
; 142(5): 446-459, 2023 08 03.
Article
in English
| MEDLINE | ID: mdl-37172204
9.
First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 25(6): 744-759, 2024 Jun.
Article
in English
| MEDLINE | ID: mdl-38821083
10.
Obinutuzumab (GA-101), ibrutinib, and venetoclax (GIVe) frontline treatment for high-risk chronic lymphocytic leukemia.
Blood
; 139(9): 1318-1329, 2022 03 03.
Article
in English
| MEDLINE | ID: mdl-35108374
11.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood
; 139(2): 177-187, 2022 01 13.
Article
in English
| MEDLINE | ID: mdl-34758069
12.
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Eur J Haematol
; 112(5): 788-793, 2024 May.
Article
in English
| MEDLINE | ID: mdl-38311570
13.
Fludarabine, cyclophosphamide, and rituximab as first-line treatment in patients with chronic lymphocytic leukemia: A long-term analysis of the German CLL Study Group (GCLLSG) registry.
Eur J Haematol
; 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38693677
14.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood
; 138(19): 1805-1816, 2021 11 11.
Article
in English
| MEDLINE | ID: mdl-34086865
15.
MARCKS affects cell motility and response to BTK inhibitors in CLL.
Blood
; 138(7): 544-556, 2021 08 19.
Article
in English
| MEDLINE | ID: mdl-33735912
16.
Treatment with idelalisib in patients with chronic lymphocytic leukemia - real world data from the registry of the German CLL Study Group.
Ann Hematol
; 102(11): 3083-3090, 2023 Nov.
Article
in English
| MEDLINE | ID: mdl-37358640
17.
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
N Engl J Med
; 380(23): 2225-2236, 2019 Jun 06.
Article
in English
| MEDLINE | ID: mdl-31166681
18.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
Blood
; 135(26): 2402-2412, 2020 06 25.
Article
in English
| MEDLINE | ID: mdl-32206772
19.
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients.
Haematologica
; 107(3): 615-624, 2022 03 01.
Article
in English
| MEDLINE | ID: mdl-33730841
20.
Management of front line chronic lymphocytic leukemia.
Am J Hematol
; 97 Suppl 2: S3-S10, 2022 11.
Article
in English
| MEDLINE | ID: mdl-36125035